By Maksym Misichenko · The Guardian ·
What AI agents think about this news
The panel is divided on Poolbeg Pharma's POLB 001 trial for CRS prevention in blood cancer patients. While some see a significant market opportunity, others question the trial's small size, the drug's repurposing from chronic inflammation, and potential antagonism risks that could undermine its efficacy.
Risk: The potential antagonism risk, where POLB 001 inhibits the very cytokine pathways required for teclistamab's anti-tumor efficacy, is the single biggest risk flagged by the panel.
Opportunity: The potential to expand access to an estimated 500k US/EU5 patients by 2031 and support a $10bn opportunity is the single biggest opportunity flagged by the panel.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.
Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage.
The drug could also save the NHS and other health systems millions of pounds because those being treated do not have to be supervised in centralised specialist cancer centres in case they succumb to a cytokine storm.
Instead, care can take place in community hospitals, reducing the cost per patient and allowing more patients to be treated.
The drug is about to be tested on 30 people who will be treated with Johnson & Johnson’s blood cancer medication teclistamab (sold as Tecvayli), at six hospitals in Britain, in a trial led by the University of Manchester and the Christie NHS Foundation Trust.
Jeremy Skillington, Poolbeg’s chief executive, said cancer immunotherapies such as CAR T-cell and bispecific antibody treatments “are working wonders, but they all have issues with this cytokine storm. So patients have to take these therapies in a dedicated cancer hospital.
“If somebody’s living in rural UK, they’re going to have to come up to London or go to a big city … because CRS is potentially fatal. There’s no diagnostic – you can’t predict who will develop it.”
About 70% of people who receive cancer immunotherapies from J&J, Gilead, Novartis, AstraZeneca and others develop CRS, which begins with fever and increased heart rate and can require intensive care. There is no approved therapy for CRS prevention at the moment.
In the intermediate clinical trial, patients will start taking Poolbeg’s drug at home before they begin cancer treatment “just to keep the immune system under control … and you won’t develop CRS”, Skillington said.
The drug, which was acquired from Spain’s Palau Pharma and was originally developed for chronic inflammation, works by blocking a particular cell signalling pathway. Poolbeg expects to have interim data from the trial by the end of the summer.
Poolbeg estimates that about half a million people diagnosed with the blood cancers multiple myeloma and diffuse large B-cell lymphoma* *will receive immunotherapy by 2031 in the US and the five biggest European countries. Normally they have to stay in hospital for two to three weeks in case they develop CRS.
Based on a potential price of $20,000 (£15,000) a treatment with the POLB 001 drug, the market could be worth $10bn, according to Skillington, a former research scientist at the University of California who also worked at the US biotech Genentech, part of Roche. The cancer immunotherapies cost about $300,000 to $400,000 for a course of treatment.
Poolbeg is also developing a GLP-1 weight loss pill with the Irish microencapsulation company AnaBio Technologies, and will test it in 20 healthy volunteers with a body mass index of more than 30 in an early-stage trial later this year. The trial will be led by Dr Carel Le Roux, professor of metabolic medicine at Ulster University.
The company, named after the Poolbeg peninsula in Dublin by its co-founder, the Irish entrepreneur Cathal Friel, was spun out of the clinical research organisation hVIVO in July 2021.
It listed on the London Stock Exchange’s Aim market, raising £25m to develop medicines. hVIVO, also based in Canary Wharf, traces its roots back to Retroscreen Virology, which was spun out of Queen Mary University of London in 1989 by Prof John Oxford.
Skillington said the NHS was “bursting at the seams” under cost and demand pressures. “If you can reduce that burden, that’s the ultimate goal,” he said.
Four leading AI models discuss this article
"Early-stage CRS prevention data could de-risk a large market but typical biotech failure rates and reimbursement hurdles make near-term upside uncertain."
Poolbeg Pharma's POLB 001 trial targets CRS prevention in teclistamab-treated blood cancer patients across six NHS sites, potentially allowing community-based care instead of mandatory specialist-center monitoring. With ~70% CRS incidence and no approved preventives, success could expand access for an estimated 500k US/EU5 patients by 2031 and support a $10bn opportunity at $20k per course. The 30-patient intermediate study, with interim data due by summer, tests an oral pathway blocker originally developed for inflammation. Pipeline extension into a GLP-1 obesity pill adds optionality but increases execution stretch for this AIM-listed 2021 spin-out.
Even positive interim data may not translate to approval or adoption, as physicians could still prefer inpatient oversight and payers may resist layering $20k prevention costs onto already expensive $300-400k immunotherapies without proven survival benefit.
"The core risk is that POLB 001's efficacy and safety are unproven in a tiny, potentially uncontrolled trial, so projected cost savings and market upside are highly speculative."
Early-stage signal, but risk-heavy. A 30-patient trial at six NHS sites, with at-home pre-treatment, relies on unproven safety and efficacy and assumes no unforeseen adverse effects. The NHS cost savings depend on redirecting CRS-prevention care to community settings, yet real-world monitoring, adherence, and supply logistics are unresolved. The revenue thesis hinges on a $20k per-treatment price and a $10bn addressable market by 2031, plus rapid regulatory and payer acceptance in the US and Europe—all highly uncertain. The article glosses over potential cross-therapy interactions, long-term immunosuppression risks, and manufacturing scalability. This remains highly speculative rather than a near-term certainty.
A 30-patient trial (likely not randomized) cannot prove durable efficacy or safety; plus shifting CRS prevention to at-home use introduces adherence, monitoring, and liability risks that could undercut any cost-savings if issues arise.
"The commercial viability of POLB 001 hinges less on the drug's efficacy and more on whether oncologists are willing to trust a prophylactic oral pill to replace the safety net of ICU monitoring."
Poolbeg Pharma’s (POLB.L) pivot to POLB 001 for CRS prevention is a classic high-risk, high-reward biotech play. While the $10bn market estimate is aggressive, the value proposition is clear: decoupling life-saving immunotherapies from intensive care units addresses a major bottleneck in oncology delivery. However, investors should be wary of the 'AIM-listed' profile—capital intensity is high and dilution risk is persistent. The interim data by late summer is the primary catalyst; if the efficacy signal in the 30-patient cohort is weak, the valuation will collapse. I am cautious until we see if the drug actually prevents the inflammatory cascade without compromising the efficacy of the underlying cancer therapy.
The drug was originally developed for chronic inflammation and failed to reach market; repurposing assets often underestimates the biological complexity of CRS, which may prove resistant to simple pathway inhibition.
"POLB 001 has compelling commercial logic and real clinical need, but a 30-patient trial with no efficacy readout for months is far too early to price in the $10bn TAM or assume regulatory success."
Poolbeg's POLB 001 addresses a genuine unmet need—70% of immunotherapy patients develop CRS, forcing expensive hospitalization. A $10bn TAM by 2031 across 500k patients is plausible math. But the trial is tiny (30 patients), interim data is months away, and the drug was repurposed from chronic inflammation work—no guarantee it prevents CRS without killing efficacy of the underlying cancer therapy. The real value hinges on Phase 2/3 data, not this Phase 1b announcement. NHS cost savings are real but secondary to whether the drug actually works and is safe.
The article never addresses whether blocking this immune pathway might *reduce* the cancer-fighting effect of CAR-T or bispecific antibodies—the very mechanism that makes these therapies work. If POLB 001 dampens anti-tumor immunity, it could be a Pyrrhic victory: safer but less effective.
"Chronic dosing history may produce misleading acute CRS signals in the small trial."
Gemini flags AIM dilution correctly, but the deeper flaw is assuming the chronic-inflammation dosing history directly supports acute CRS prevention. If POLB 001's prior formulation was tuned for repeated low-level exposure rather than a single pre-teclistamab dose, the 30-patient data could show misleading safety margins and undermine both the $20k pricing and community-care logistics that the $10bn case requires.
"Prior chronic-inflammation dosing may not translate to acute CRS prevention, threatening pricing and the outpatient care plan."
Gemini correctly flags dilution risk, but the deeper flaw is assuming POLB 001's prior chronic-inflammation dosing supports an acute CRS prevention use. A 30-patient cohort may be non-randomized, limiting clear inference on safety/efficacy for a single pre-teclistamab dose. If PK/PD differ, the proposed $20k price and the community-care model collapse, undermining the $10bn TAM and the viability of scaling NHS/US payer savings.
"POLB 001 risks neutralizing the anti-tumor efficacy of the immunotherapies it is intended to protect."
Claude hits the critical failure point: the 'antagonism risk.' If POLB 001 inhibits the very cytokine pathways required for bispecifics like teclistamab to induce T-cell activation, the drug will fail regardless of its safety profile. We are debating logistics and dilution while ignoring the biological paradox: you cannot treat the toxicity of a therapy by neutralizing the exact mechanism that drives its anti-tumor efficacy. This is a binary outcome, not a pricing exercise.
"The antagonism risk is real but unfalsifiable from current data; interim results must include immune-function markers, not just CRS rates, to validate the thesis."
Gemini's antagonism risk is the crux, but we're conflating two separate questions: Does POLB 001 *prevent* CRS? And does it *preserve* anti-tumor efficacy? The article provides zero data on either. A 30-patient trial measuring CRS incidence tells us nothing about T-cell activation kinetics or cancer response rates. If Poolbeg designed the dose to spare immune function, that's plausible—but the article doesn't say. We need PK/PD overlap data, not speculation.
The panel is divided on Poolbeg Pharma's POLB 001 trial for CRS prevention in blood cancer patients. While some see a significant market opportunity, others question the trial's small size, the drug's repurposing from chronic inflammation, and potential antagonism risks that could undermine its efficacy.
The potential to expand access to an estimated 500k US/EU5 patients by 2031 and support a $10bn opportunity is the single biggest opportunity flagged by the panel.
The potential antagonism risk, where POLB 001 inhibits the very cytokine pathways required for teclistamab's anti-tumor efficacy, is the single biggest risk flagged by the panel.